CNBX Pharmaceuticals Inc
cnbxpharma.comCNBX Pharmaceuticals Inc (CNBX) is a clinical-stage pharmaceutical company developing cannabinoid-derived drug candidates for cancer treatment. The company generates no product revenue as of the fiscal year ended August 31, 2025, operating entirely in the research and development phase. Its pipeline centers on RCC-33, a synthetic cannabinoid-based formulation targeting colorectal cancer as a neoadjuvant therapy, and Cannabics CDx, an ex-vivo drug sensitivity test designed to guide cannabinoid therapy selection for cancer patients. Chemistry, manufacturing, and controls work is fully outsourced, with Purisys identified as a planned supplier of GMP-grade active pharmaceutical ingredients for anticipated Phase I/II clinical studies. CNBX has not established sales, marketing, or distribution infrastructure. The company carries an accumulated deficit, holds convertible loan obligations, and has amounts due to a related party, reflecting a balance sheet typical of a pre-revenue drug development entity. The company is also developing Cannabics SR, a dietary supplement subject to FDA and FTC regulation in the United States and Ministry of Health oversight in Israel.
Products & Services
RCC-33: synthetic cannabinoid-based drug candidate targeting colorectal cancer via neoadjuvant therapy. Cannabics CDx: ex-vivo drug sensitivity test for identifying effective cannabinoid combinations in cancer patients. Cannabics SR: dietary supplement subject to FDA, FTC, and Israeli Ministry of Health regulation.
Revenue Model
No product revenue is disclosed in the fiscal year ended August 31, 2025 filing. The company is pre-commercial, funding operations through capital raises rather than product sales.
Customers & Markets
End market is oncology, specifically colorectal cancer treatment. Intended customers are healthcare providers and cancer patients. No commercial customers are disclosed as of August 31, 2025.
Geographic Exposure
United States primary regulatory jurisdiction via FDA and DEA. Israel identified as an additional regulatory jurisdiction for dietary supplement products via Ministry of Health.
Financial Snapshot
Loading...
